What to expect with SOMAVERT

SOMAVERT is the only medication that blocks GH activity in the liver

SOMAVERT is a prescription medicine for patients whose acromegaly has not been controlled by surgery or radiation. SOMAVERT blocks growth hormone (GH) from signaling the body to produce too much insulin-like growth factor I (IGF-I).

- Blocking GH activity helps to reduce levels of IGF-I
- Having less IGF-I in the body may help improve some of the signs and symptoms of acromegaly

The goal of treatment with SOMAVERT is to have a normal IGF-I level in the blood

SOMAVERT was shown to help patients with acromegaly significantly lower IGF-I levels

SOMAVERT was studied in a clinical trial for 12 weeks in 112 patients. Patients were given either a daily dose of SOMAVERT at 10 mg, 15 mg, or 20 mg, or they were given a placebo. **For all 3 doses in the 12-week clinical trial, SOMAVERT:**

Significantly lowered IGF-I levels at 12 weeks*

Rapidly reduced IGF-I levels within 2 weeks*

Worked for 2 out of 3 patients to achieve normal IGF-I levels*

SOMAVERT works to reduce signs and symptoms of acromegaly

SOMAVERT improved ring size and total score of signs and symptoms of acromegaly (swelling, joint pain, headache, sweating, and weakness) compared to placebo in the 12-week trial.

What are the most common side effects of SOMAVERT?

The most common side effects with SOMAVERT are infection, pain, nausea, diarrhea, abnormal liver function tests, flu-like symptoms, and reaction at the injection site. These are not all of the possible side effects of SOMAVERT. For more information, speak to your doctor.

*These data are from a clinical trial that involved 112 patients with acromegaly. Thirty-two patients received a placebo. Eighty were treated with SOMAVERT at 1 of 3 dosage strengths. The primary efficacy endpoint was IGF-I percent change in IGF-I concentrations from baseline to week 12. The mean percent change from baseline in IGF-I was -4 for placebo, -27 at 10 mg/day, -48 at 15 mg/day, and -63 at 20 mg/day for SOMAVERT. Seventy-five percent of the total mean reduction in IGF-I levels occurred within 2 weeks and the reduction was sustained over the 12-week course of therapy with all doses of SOMAVERT (this was not part of the primary endpoint). Results of the secondary endpoint for percent of patients achieving normal IGF-I levels for their age were 10% of patients taking a placebo, 39% of those on 10 mg of SOMAVERT per day, 75% of those on 15 mg of SOMAVERT per day, and 82% of those on 20 mg of SOMAVERT per day. The total percentage of patients taking SOMAVERT who achieved normal IGF-I levels at week 12 was 65% (51 out of 78 patients).

INDICATION

SOMAVERT is a prescription medicine for acromegaly. It is for patients whose disease has not been controlled by surgery or radiation, or patients for whom these options are not appropriate. The goal of treatment with SOMAVERT is to have a normal IGF-I level in the blood.

SELECTED SAFETY INFORMATION

Do not use SOMAVERT® (pegvisomant for injection) if you are allergic to SOMAVERT or anything that is in it.

Be sure to tell your doctor if you use narcotic painkillers (opioid medicines) because the dose of SOMAVERT may need to be changed.

Blood sugar levels may go down when taking SOMAVERT. Be sure to tell your doctor if you use insulin or other medicines (oral hypoglycemic medicines) for diabetes. The dose of these medicines may need to be reduced when you use SOMAVERT.

Please see additional Selected Safety Information on reverse and full Prescribing Information attached.

SOMAVERT®
(pegvisomant for injection)

Patient resources and more

Pfizer Bridge Program®

Starting a new medicine can mean lots of questions—and sometimes hurdles—to getting your treatment. That's why Pfizer created the Pfizer Bridge Program.*

When you enroll in the Pfizer Bridge Program, you are assigned a dedicated Patient Care Consultant who can assist you with:

- Evaluating your insurance coverage
- Coordinating between you, your doctor's office, your insurance company, and your specialty pharmacy
- Arranging for a nurse to connect with you virtually or come to your home to teach you how to inject SOMAVERT if requested by your doctor

*Certain programs and services powered by Pfizer RxPathways®.

We encourage you to call the **Pfizer Bridge Program** for more information about this program and other patient support offerings from 9 AM to 7 PM Eastern Time, Monday through Friday, at **1-800-645-1280**. For specific questions about taking SOMAVERT, be sure to talk to your doctor.

SOMAVERT is available in original one-day packaging or 30-day packaging and with more storage options, including room temperature for a single period of up to 30 days

STAY ON TRACK WITH SOMAVERT

Sign up to "Stay on Track With SOMAVERT" by visiting **SOMAVERT.com** to receive resources to help you better understand and track your treatment journey.

INDICATION

SOMAVERT is a prescription medicine for acromegaly. It is for patients whose disease has not been controlled by surgery or radiation, or patients for whom these options are not appropriate. The goal of treatment with SOMAVERT is to have a normal IGF-I level in the blood.

SELECTED SAFETY INFORMATION

Some people who have used SOMAVERT have developed liver problems. These problems generally disappeared when those people stopped taking SOMAVERT.

Stop the drug right away and call your doctor if you get any of these symptoms:

- Your skin or the white part of your eyes turns yellow (jaundice)
- Your urine turns dark
- Your bowel movements (stools) turn light in color
- You do not feel like eating for several days
- You feel sick to your stomach (nausea)
- You have unexplained tiredness
- You have pain in the stomach area (abdomen)

Your doctor may do blood tests before and during your treatment with SOMAVERT to check that the IGF-I levels in your blood are normal and/or that your liver is working correctly. Your dose of SOMAVERT may be changed based on the results of these tests.

If you have stopped SOMAVERT because of an allergic reaction, your doctor will carefully monitor what happens if you start SOMAVERT again.

The most common side effects with SOMAVERT are infection, pain, nausea, diarrhea, abnormal liver function tests, flu-like symptoms, and reaction at the injection site. These are not all of the possible side effects of SOMAVERT. For more information, speak to your doctor.

Inject SOMAVERT in a different place on your body each day. This can help prevent skin problems such as lumpiness or soreness.

SOMAVERT has not been studied in pregnant women. It is not known if SOMAVERT passes into the mother's milk or if it can harm the baby.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/Medwatch or call 1-800-FDA-1088.

Please see additional Selected Safety Information on front and full Prescribing Information attached.

SOMAVERT® (pegvisomant for injection)